Enclomiphene vs clomid: is the purified isomer worth it?
Enclomiphene is clomiphene's isolated active half. It doesn't raise testosterone more — clomiphene did, on average — but it's cleaner on estradiol and side effects.
Because enclomiphene is literally a piece of clomiphene, the obvious question is whether paying for the purified version buys you anything. The honest answer is nuanced: it does not reliably raise testosterone more, but it does appear to do so more cleanly. Which one wins depends on whether you value raw potency or tolerability. For the standalone evidence behind enclomiphene, see our enclomiphene evidence monograph.
Same drug family, one isolated half
Clomiphene citrate is a racemic mixture of two mirror-image isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). Enclomiphene is the half that drives the rise in gonadotropins; zuclomiphene is longer-lived and more estrogenic. Enclomiphene the drug is simply clomiphene purified down to that active trans-isomer — the entire pharmacological rationale was that isolating it would give a cleaner effect.[3] So this is not two different drugs; it is a mixture versus one of its components.
| Enclomiphene | Clomiphene (clomid) | |
|---|---|---|
| What it is | Purified trans-isomer | Mixture of trans + cis isomers |
| Testosterone rise | +7.50 nmol/L (meta-analysis) | +11.56 nmol/L (meta-analysis) |
| Estradiol change | Smaller (−5.92 pg/dL) | Larger (+17.50 pg/dL) |
| Adverse events | Fewer (OR 0.18 vs clomiphene) | More |
| Cost & availability | Pricier, compounded | Cheaper, widely available |
| FDA-approved for men? | No — off-label | No — off-label (approved only in women) |
Does enclomiphene raise testosterone more? Not on average
This is the finding the marketing usually skips. A 2023 systematic review and meta-analysis found clomiphene raised testosterone more than enclomiphene, not less: a mean increase of +11.56 nmol/L (95% CI 9.68–13.43) for clomiphene versus +7.50 nmol/L (95% CI 6.52–8.48) for enclomiphene.[1] Even after excluding one study in severely obese men, clomiphene’s effect stayed larger at +10.27 nmol/L.[1] If the only goal is the testosterone number on a lab report, the cheaper mixture did at least as well.
- Clomiphene11.56 nmol/L
- Enclomiphene7.5 nmol/L
A direct head-to-head muddies it slightly in enclomiphene’s favor but not significantly: in a 66-man retrospective comparison, enclomiphene’s median testosterone rise (+166 ng/dL) was numerically larger than clomiphene’s (+98 ng/dL), but the difference was not statistically significant (P = 0.20).[2] The fair summary across both: on testosterone, the two are roughly a wash, and if anything the pooled data leans clomiphene.
Where enclomiphene actually wins: estradiol and tolerability
The case for the purified isomer rests on a cleaner side-effect and estrogen profile. In that same head-to-head, enclomiphene produced a much smaller estradiol change than clomiphene (−5.92 vs +17.50 pg/dL; P = 0.001) and was associated with significantly lower odds of adverse events overall (OR 0.18; 95% CI 0.07–0.44; P = 0.02).[2]Specifically, decreased libido (P = 0.001), reduced energy (P = 0.044) and mood changes (P = 0.03) were all less common on enclomiphene.[2] That is the trade in one line: similar (or slightly lower) testosterone, materially fewer side effects. The fuller side-effect picture is in our enclomiphene side effects breakdown.
The honest bottom line
Enclomiphene is not a more powerful clomiphene — on average it raises testosterone slightly less.[1] What it offers is refinement: a smaller estrogen bump and significantly better tolerability in the one head-to-head we have.[2] For a man who tolerates clomiphene fine, the cheaper mixture is reasonable; for a man bothered by mood, libido or estrogen-related effects on clomiphene, enclomiphene is the logical step. Both are off-label, compounded, and short on long-term data, so the choice is best made with a clinician who can monitor the response. See also enclomiphene vs TRT and the dosage guide.
Reviewed against primary sources by the Aminoscope desk
Sources
- [1] Tienforti D, Castellini C, Di Giulio F, et al. (2023). Selective estrogen receptor modulators for functional hypogonadism in men: a systematic review and meta-analysis. Andrology. PMID 36604313
- [2] Saffati G, Seyan Z, Hayman J, et al. (2024). Comparing the effects of enclomiphene and clomiphene citrate in the management of hypogonadism. Transl Androl Urol. PMID 39434750
- [3] Earl JA, Kim ED. (2019). Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. PMID 31063005